SXTC

China SXT Pharmaceuticals, Inc.
CAPPED RATING

China SXT Pharmaceuticals, Inc. (SXTC) is rated D+ (1.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Momentum (F). The rating has held at D+ for 2 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.8 / 5.0
D+
Value
B
Factor Score 3.3 / 5.0
Growth
D-
Factor Score 0.8 / 5.0
Profitability
C
Factor Score 2.2 / 5.0
Momentum
F
Factor Score 0.3 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio N/A
EV / EBITDA 3.7
Rev Growth YoY -43.9%
Gross Margin 21.9%
Price Return 3M -99.2%
Price Return 12M -100.0%
Catalyst Signal 0.00
Market Cap $310.7K
TTM Revenue $1.1M
Price / Sales 0.3
ROE -27.5%

Historical Factor Score Progression

Held D+ for 2 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 B (3.3) D- (0.8) C (2.2) F (0.3) C+ (2.6) D+ (1.8)
2026-11-08 B (3.3) D- (0.8) C (2.2) F (0.2) C+ (2.6) D+ (1.8)
2026-11-01 B (3.3) D- (0.8) C (2.2) F (0.2) C+ (2.7) D+ (1.8)
2026-10-25 B (3.3) D- (0.7) C (2.2) C+ (2.5) C+ (2.6) C (2.3)
2026-10-18 B (3.2) D- (0.7) C (2.2) F (0.3) C+ (2.6) D+ (1.8)
Page 1 of 4